NCT02090374View on ClinicalTrials.gov

Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen

NACompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Allergic RhinitisAsthmaLatent Tuberculosis
Interventions
OTHER

Poly ICLC

Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug

OTHER

Poly I:C

Single dose: 500ug

OTHER

R848

High dose: 10ug Low dose: 1-2ug

OTHER

Timothy Grass Pollen

Dose: 5000 SQ-U/100µl

OTHER

Vitamin D

4000U orally

OTHER

Tuberculin

Tuberculin PPD

Trial Locations (1)

W2 1NY

Imperial Clinical Respiratory Research Unit (ICRRU), St Mary's Hospital, Paddington

All Listed Sponsors
lead

Imperial College London

OTHER

NCT02090374 - Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen | Biotech Hunter | Biotech Hunter